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Hyaluronan is a simple repeating disaccharide polymer, synthesized at the cell surface by
integral membrane synthases. The repeating sequence is perfectly homogeneous, and is
the same in all vertebrate tissues and fluids. The polymer molecular mass is more variable.
Most commonly, hyaluronan is synthesized as a high-molecular mass polymer, with an
average molecular mass of approximately 1000–8000 kDa. There are a number of studies
showing increased hyaluronan content, but reduced average molecular mass with a
broader range of sizes present, in tissues or fluids when inflammatory or tissue-remodeling
processes occur. In parallel studies, exogenous hyaluronan fragments of low-molecular
mass (generally, <200 kDa) have been shown to affect cell behavior through binding
to receptor proteins such as CD44 and RHAMM (gene name HMMR), and to signal
either directly or indirectly through toll-like receptors. These data suggest that receptor
sensitivity to hyaluronan size provides a biosensor of the state of the microenvironment
surrounding the cell. Sensitive methods for isolation and characterization of hyaluronan
and its fragments have been developed and continue to improve. This review provides an
overview of the methods and our current state of knowledge of hyaluronan content and
size distribution in biological fluids and tissues.
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Introduction
Hyaluronan (hyaluronic acid, HA) is found in vertebrate tissues, as a key component of the
extracellular matrix. It has a simple covalent structure consisting of alternating β--glucuronate
and N-acetyl-β--glucosamine sugars. The linear anionic polymer has a semi-flexible structure,
causing it to adopt an expanded wormlike random coil. The domain of a coiled chain can be
conceptually described as a sphere [mostly filled with (unbound) solvent], with a dynamically
changing chain configuration. The apparent volume occupied by a single isolated molecule depends
strongly on the chain length, and thus the molecular mass,M. The volume increases approximately
as M raised to the 1.8 power, as dictated by polymer chain statistics (1). Where HA chains
are crowded together, their domains are forced to interpenetrate, and this leads to severe non-
ideality in behavior. The non-ideality determines such properties as the large colloid osmotic
pressure, viscoelasticity, and effect on partition of other macromolecules (excluded volume) in the
biomatrix. Since the molecular mass of HA in normal biological fluids and tissues is normally
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very high (ca. 1000–8000 kDa), the non-ideality effects domi-
nate the physicochemical properties of HA in the extracellular
matrix (2–4).
In addition to the physicochemical effects due tomutualmacro-
molecular crowding, HA has important binding interactions. At
the cell surface, HA provides a protective coat that is tethered
to receptors embedded in the cell membrane (5–7). Beyond the
cell surface, HA organizes proteoglycans (e.g., versican, aggre-
can) and other binding proteins via specific non-covalent inter-
actions, creating a further highly hydrated and charged domain
(8–10). In inflammation and other specific tissue-remodeling
processes, covalent transfer of the heavy chain domains of IαI
to HA can be catalyzed by TSG-6 protein (11–14). The HA-
protein assemblies, whether covalently or non-covalently medi-
ated, are integral to maintenance of an expanded pericellular
matrix.
Normally, HA has a high turnover rate (15, 16). Thus, the extra-
cellular environment is constantly renewed. The need for renewal
may reside in the protective role HA fulfills. Facile degradation
of HA by reactive oxygen and nitrogen species (ROS/RNS) (17,
18) during active inflammation can weaken the protective HA
coat that usually protects the cell. The HA acts as a scavenger of
damaging free radicals and other chemical agents. If the rate ofHA
synthesis keeps pace with the rate of degradation and turnover, the
homeostatic environment is maintained (19).
When the rate of HA degradation is not adequately com-
pensated by its synthesis, fragments of the polymer might be
present at significant levels and consequently cells are poorly
protected. Changes in the physicochemical control of the pericel-
lular environment take place. HA fragments compete in binding
interactions with proteins, altering the integrity of the bioma-
trix. Fragments can displace high M HA in interactions with
cell surface receptors, resulting in changes in receptor clus-
tering and altered signaling (20). Fragments can also signal
through alternate receptors (21–23). In these ways, HA may
be regarded as a biosensor of damaging processes in the cel-
lular microenvironment. Altering the balance of high and low
M HA is a stimulus that sets in motion multiple cellular
response mechanisms. These can be purely defensive, such as HA
fragment-induced expression of β-defensins to combat micro-
bial infection in the gut (24, 25). But sustained responses can
also lead to chronic inflammation via aberrant signaling through
receptors and consequently increased expression of inflammation
mediators (26).
Tissue-remodeling processes, including wound healing and
tumor progression, are associated with changes inHA content and
size (27–31). HA synthesis is usually increased during remodeling,
but increased expression of hyaluronidases may also occur, and
together withmacrophage-generated ROS/RNS, degradeHA. The
balance of high and low M HA may differ from the homeostatic
case, thus altering both the physicochemical and signaling effects
of HA. To understand HA biology, we are faced with multiple
questions: (1) What is the content of HA present, (2) What is the
molecular mass distribution of the HA, and (3) Can we control
pathological processes by altering the content, size, and binding
interactions of HA?
Isolation of HA
There are a number of methods appropriate for assaying the
content and size of HA in biological fluids and tissues. Depending
on the method, it may be necessary to purify HA to remove/digest
bound proteins and sulfated glycosaminoglycans prior to assay.
The isolation of HA follows protocols (25, 30, 32–35) that are
quite similar to those historically employed in the purification of
DNA. The requirement for specific steps depends on the nature
of the sample: fluid tissue vs. conditioned medium from cell
culture vs. solid tissue. For solid tissues, the HA is extracted into
soluble form, and liberated from proteins. Protein removal can
be accomplished by digestion with a protease, or by denaturing
the protein by gentle mixing with chloroform. Lipids are removed
with acetone or other organic solvent mixtures. Removal of low-
molecular mass contaminants may require dialysis, or precipita-
tion of the HA with ethanol or isopropyl alcohol. DNA and RNA
can be enzymatically digested. There are many variations on these
steps. A sample protocol for extraction of HA from solid tissue
might include the following steps: digestionwith a protease such as
proteinase K, boiling to denature enzyme, centrifugation, extrac-
tion with chloroform, centrifugation, dialysis, precipitation with
ethanol, centrifugation, re-dissolution, digestion with Benzonase
(or DNase plus RNase), boiling to denature enzyme, and repeat of
steps starting with chloroform extraction. Abbreviated protocols
can be used for fluid samples, or where the HA needs to be
liberated but not purified because specific assay will be employed.
The above purification will not remove other glycosamino-
glycans. Sulfated glycosaminoglycans can be removed by anion
exchange chromatography. Unsulfated or undersulfated chon-
droitin, which is rare in normal tissues but may be significant in
remodeling tissues, is not removed by this process. At this point
in the procedure, specific isolation of HA can be accomplished by
affinitymethods, such as use of a biotinylatedHA-specific binding
protein and streptavidin-coated magnetic beads, or other similar
medium such as gel beads (36, 37).
It is worth noting that most isolation methods in current use
have not been validatedwith respect to quantitative yield ofHA, or
preferential extraction/isolation of specific HA sizes. In particular,
losses of very low M HA may be significant in some procedures.
It is also possible to degrade HA during isolation. Endogenous
enzymes may cause some of this degradation. However, most
degradation is the result of ROS generation catalyzed by contami-
nating iron (II) or copper (I), and molecular species that regen-
erate the active metal ion oxidation states. Thus, use of papain
activated with cysteine can lead toHA degradation (38). The pres-
ence of EDTA can also enhance the ability of contaminating iron
to catalyze formation of hydroxyl radicals. Iron contamination is
better inactivated by chelation with deferoxamine (34). Also, of
note, EDTA and phosphates can be co-precipitated with HA using
ethanol.
Testing for degradation of HA during isolation can be easily
accomplished by “spiking” the initial fluid or tissue with a pure
HA sample of known M and low polydispersity in M, and then
testing its size in the final isolate. Spiking samples with known
amounts of HA can also be used to detect losses during isolation,
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including losses due to non-specific interactions with surfaces or
other macromolecules that HA may not normally contact.
Methods to Analyze Content of HA
The most simple and historical assay for HA is measurement of
uronic acid content. The assay involves hydrolysis in concentrated
sulfuric acid, so that protein content is not a problem. Other
glycosaminoglycans that contain uronic acid will contribute to the
result, and should be separated or removed from HA if possible.
The uronic acid assay has been widely employed, especially in
analysis of fluids (synovial fluid, vitreous) with high HA and low
sulfated glycosaminoglycan content.
Hyaluronic acid content can be also determined by analysis
of the oligosaccharide products of enzymatic digestion. Quan-
tification is accomplished by methods such as HPLC, capillary
electrophoresis (CE), mass spectrometry, or fluorophore-assisted
carbohydrate electrophoresis. Thesemethods have primarily been
employed to determine relative amounts of different glycosamino-
glycans in a sample, rather than absolute quantities.
Themost sensitive, specific, and accurate methods for determi-
nation of HA content are based on enzyme-linked sorbent assays
(ELSA, ELISA-like assays) (39–47). The specific detection of HA
is an important step of these methods, because purification of low
M HA is difficult, and contaminants interfere with non-specific
detection modes. The specificity is based on the use of molecular
species such as proteins or proteoglycans that recognize and bind
HA but no other biological molecules. For example, the aggrecan
proteoglycan binds HA specifically (8, 9). The intact proteoglycan
may be used, or a terminal fragment called globular domain 1 –
interglobular domain – globular domain 2 (G1–IGD–G2), often
referred to as HA-binding protein (HABP) or HA-binding region
(HABR). The link protein, also called CRTL1 or HAPLN1, is
similar to the G1 domain of aggrecan, and is another suitable
protein for specific detection of HA. Isolated HABP, usually a
mixture of the aggrecan HABR and the link protein, may also
be used. Similarly, versican proteoglycan G1 domain is useful.
Hyaluronectin, a HA-specific binding protein isolated from brain,
may be used. Recently, a recombinant fusion protein of human
TSG-6 and the Fc domain of human IgG, and a second variant of
the fusion protein in which the heparin-binding region of TSG-
6 was mutated to become inactive, were found to be suitable
for development of a specific HA assay (47). Other HA-specific
binding molecules could be used.
There are two types of ELSA. The first type, sandwich assays,
are sensitive and reproducible, but fail to adequately quantify low
M HA (39–42). This is because the plate surface, coated with an
HABP, strongly binds HA, but does not allow further probing of
short HA chains by the detector protein (43). Longer HA chains
have accessibility as a result of looped sections above the surface.
(The same problem occurs in HA blotted to positively charged
nylon membranes after electrophoresis, from which short HA
chains cannot be detected.) The second type of ELSA is com-
petitive assays. In these, HA is usually immobilized on a surface
such as the wells of a plastic 96-well plate. Alternative surfaces
are suitably modified magnetic beads. Soluble HA samples, either
standards or unknowns, aremixedwith the specific binding agent,
usually a protein or proteoglycan. The soluble HA competes with
immobilized surface HA for the specific binding agent, so that the
resulting surface-bound amount of the binding agent is a measure
of the amount of soluble HA in the sample being analyzed (41, 44,
45). There are multiple possible detection schemes to quantify the
bound agent. For example, if aggrecan proteoglycan is the specific
binding agent, it can be quantified with an antibody to the keratan
sulfate chains of aggrecan, and a suitably labeled second antibody.
When the specific binding agent is a labeled (e.g., biotinylated)
HABP, it can be quantified by binding of the label to a specific
agent such as streptavidin, which is, in turn, conjugated to an
enzyme or other detectable species. Radiolabeled HABP may also
be used but is less desirable on the basis of safety and disposal.
Because the recognition step in a competitive binding assay occurs
in solution, HA chains as short as approximately decasaccharides
can be accurately detected, depending on the labeled binding
protein used. The results of sandwich and competitive assays have
been shown to be in good agreement for highM HA (46).
HA Content in Biological Fluids and Tissues
The content of HA in many normal biological fluids has been
determined. Here, we cite a few relevant results. HA is a major
component of articular joint synovial fluid, where it provides the
viscoelasticity and lubrication necessary for protection of cartilage
surfaces. Its concentration in the human knee joint is approxi-
mately 2–3mg/ml, being slightly higher in younger adults than in
older adults (48–50). HA is also amajor component of the vitreous
body of the eye, but at a lower concentration of approximately
200µg/ml, in the phakic human eye vitreous (51). The concentra-
tion in the aqueous humor is lower still, being only about 1µg/ml
(52). Human lymph fluid contains HA at a concentration of about
0.1–18µg/ml (36). In the blood serum of healthy human adults,
the concentration of HA is lower still, being usually between 10
and 100 ng/ml,mostly 20–40 ng/ml, and averaging about 30 ng/ml
(36, 40, 44). Normal human urine also contains a low level of HA,
around 100–300 ng/ml (44), and human milk similarly contains
HA at about 200–800 ng/ml (25).
The HA content of solid tissues varies widely. Bovine nasal
cartilage contains approximately 1200µg HA/g wet tissue weight
(44). TheHA content of human articular cartilage is similar, being
about 500–2500µg/g (53). Human skin contains approximately
400–500µg HA/g tissue, mostly in the dermis (54). Fetal skin
and young skin have higher HA contents than older skin. Other
organs have much less HA. Laurent and Tengblad (44) reported
HA contents of approximately 1–100µg HA/g wet tissue weight
for most organs. Rabbit kidney had 103µg/g, brain had 65µg/g,
muscle had 27µg/g, liver had 1.5µg/g, and cornea had 1.3µg/g.
Armstrong andBell (34) also reported rabbit tissueHA contents of
500µg/g for skin, 200µg/g for large intestine and heart, 130µg/g
for small intestine, and 80–90µg/g for lung and muscle tissues.
Measurement of HA content is of continuing high interest,
because there are multiple studies correlating changes in HA con-
tent with tissue remodeling and pathological processes. While the
normalHA concentration in human serum is usually <40 ng/ml, it
is elevated (>46.5 ng/ml) in hepatic cirrhosis (55), in rheumatoid
arthritis (56, 57) (highly variable; reports up to nearly 200µg/ml,
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but more generally between 0.07 and 6.4µg/ml), in ankylos-
ing spondylitis (57) (7–13µg/ml), and in osteoarthritis (57, 58)
(0.04–2.3µg/ml). The elevated HA concentration in serum of
patients with hepatic cirrhosis is utilized as one component of
a diagnostic assay. A small but significant elevation (frequently,
about twofold) of HA in serum is found in multiple types of
untreated cancer (59–61). Radical surgery to remove the tumor
causes the HA concentration in serum to return to the normal
range. Most interestingly, it was found that the low-molecular
mass component of serum HA can be used to differentiate
metastatic from non-metastatic breast cancer (62), which may
form the basis of a new diagnostic test.
In solid tissues, many but not all cancers progress in a tumor
microenvironment of increased HA content (28). Further, some
non-aggressive cancer types such as non-malignant fibroadenoma
produce elevated HA (63, 64). The presence of HA may therefore
not be sufficient by itself to promote tumorigenesis. However,
high levels of HA accumulate in lung, colorectal, prostate, bladder,
and breast carcinomas and in these cancers are linked to tumor
aggression (28). For example, theHAcontent of human lung tissue
increases 4- to 200-fold in lung carcinoma (65), 100-fold in grade
3 ovarian cancer (66) and 7-fold in prostate cancer (67). Increased
tumor HA accumulation is also linked to tumor aggression. The
HA content of malignant ovarian epithelial tumor correlates with
tumor grade and with metastasis. Elevated HA accumulation
within the stroma or tumor parenchyma of breast cancer is associ-
atedwith unfavorable prognosis of the patient. Recent studies have
further linked high stromal HA staining to HER2 positive tumors
and poor outcome parameters including time to relapse, large
tumor size, lymph node positivity, hormone receptor negativity,
high body mass, and shortened overall survival (68). Elevated
HA in the tumor microenvironment is linked to inflammation
(69). Thus, high amounts of both tumor-associated macrophages
and HA are concurrent in breast carcinoma. High macrophage
numbers correlate with high tumorHA,HAS expression and poor
outcome, suggesting that HA facilitates a macrophage tumor sup-
porting function in breast cancer. The link between inflammation
and cancer has led to recent interest in HA as a contributor to
a pro-tumorigenic inflammatory environment, as detailed in a
companion article in this issue (70).
As for cancer, wound healing and fibrosis are associated with
inflammation and increased HA content (71). An approximately
twofold increase was observed in HA content of rat skin during
healing of excisional wounds (30). Similarly, scleroderma patients
with early stage disease have an approximately twofold increase
in serum HA (72). Many other pathological states characterized
by inflammation similarly have elevated HA, as estimated by
immunohistochemical analyses (73, 74).
Methods to Analyze HA Molecular Mass
Distribution
It has long been appreciated that degradation of HA negatively
affects its biomechanical properties. For example, degradation of
HA in articular joint synovial fluid can reduce the viscosity and
elasticity of the synovial fluid, and has also been shown to reduce
its lubricating ability (49, 75). The widespread and successful
uses of solutions of high molecular mass HA as a viscosurgical
tool in ophthalmic surgery, and as an analgesic treatment for
osteoarthritis, are based on this understanding. More recently,
the discovery that exogenous HA fragments can alter cellular
behavior by signaling throughmultiple receptor proteins, and that
the existence of such fragments in vivo is likely, based on increased
hyaluronidase levels and reactive oxygen and nitrogen species in
tissue remodeling and pathological processes, has led to increased
interest in measuring the size distribution of HA in biological
fluids and tissues.
Many current methods for determination of theM distribution
of HA from tissues and biological fluids have been optimized
for highly purified HA. A commonly employed method used
commercially is size exclusion chromatography with multiangle
laser light scattering (SEC-MALLS) (76, 77). However, detection
of very lowM HA by light scattering is inherently insensitive, and
the SEC-MALLS method requires a highly purified HA sample.
CE (78) is similarly limited to pure HA samples. MALDI-TOF
mass spectrometry (79, 80) has high sensitivity, but requires a pure
sample andHAwithM larger than about 10 kDa becomes difficult
to analyze. A new method that has extremely high sensitivity and
works best for low M HA is gas-phase electrophoretic mobility
molecular analysis (GEMMA), but it still requires pure HA (81).
The most widely used methods, to date, for size distribution
analysis of imperfectly pure HA isolated from biological samples
are size exclusion chromatography with enzyme-linked sorbent
assay (SEC-ELSA) (36, 56, 82), and agarose or polyacrylamide
gel electrophoresis (83–86) with staining or with blotting and
specific detection. Both methods are capable of detecting a wide
range of HA sizes. Gel electrophoresis with staining can analyze
samples on the microgram scale, and can tolerate some impurities
in the sample, but non-specific staining by those impurities can
interfere with size distribution analysis of the HA. Blotting of gels
to positively charged nylon and detection of HA using a labeled
specific binding protein works only for HA withM >100 kDa, as a
result of strong surface binding (43). To address the issues of lim-
ited sample amount, purification difficulty, and the importance of
analyzing both high and low M HA simultaneously, we recently
developed a method using size-dependent fractionation of HA by
anion exchange on a spin column, and quantification of HA in
the fractions using a competitive ELSA assay (IEX-ELSA) (37). All
of these methods require calibration with purified HA samples of
known size.
HA Size in Biological Fluids and Tissues
The averageM and distribution ofM for HA present in biological
sources have been studied primarily for fluid tissues such as
synovial fluid, vitreous, serum, lymph, and milk. Until recently,
the emphasis has been on documenting reduction of the average
M, which strongly affects the biomechanical properties of HA
solutions (48, 87–89). This has been done using physicochemical
methods such as viscometry, light scattering, and sedimenta-
tion–diffusion. Interest in the distribution of sizes present, and
the possibility that specific sizes have unique biological effects, has
led to an increasing number of studies by chromatographic and
electrophoretic separation methods.
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FIGURE 1 | Example molecular mass distributions of human synovial
fluid (SF) HA determined by agarose gel electrophoresis. From top to
bottom: (A) normal human SF obtained from young healthy volunteers.
(B–D) Representative osteoarthritis (OA) patient SF. The dashed vertical line
corresponds to the migration position of 4000 kDa HA. The fraction of HA
having slower electrophoretic migration, and thus higher M than 4000 kDa, is
a measure of the high M HA content. In normal human SF, the portion of HA
with M>4000 kDa averaged 61%. OA patients varied in the extent of HA
degradation. The OA-HIGH profile, similar to that seen in normal SF and
representative of OA samples with more than 60% of HA having
M>4000 kDa, was found for 26% of patients. The OA-MEDIUM profile,
representative of OA samples with approximately 41–60% of HA having
M>4000 kDa, was found for 41% of patients. The OA-LOW profile,
representative of OA samples with <40% of HA having M>4000 kDa, was
found for 33% of patients. From Lee (90).
In normal human synovial fluid, most of the HA is very high in
molecular mass. Gel filtration chromatography with HA-specific
detection (50) and agarose gel electrophoresis with staining (84,
90) show the average M to be approximately 6000–7000 kDa,
with little if any HA <1000 kDa. In rheumatoid arthritis and
in osteoarthritis, HA can be partially degraded, resulting in a
broad distribution of sizes, extending perhaps down to a few
hundred kilodaltons (90, 91) (Figure 1). Normal rabbit vitreous
HA has mostly highM (2000–3000 kDa), but bovine vitreous HA
hasmostlymoderateM (500–800 kDa) (82).Owlmonkey vitreous
has very highM HA (84).
For fluids containing HA at very low concentrations, determi-
nation of the M distribution is correspondingly difficult. Despite
this, evidence for the occurrence of HA below 100 kDa (<250
disaccharides) in M is accumulating. Human milk contains
mainly HA with an average M of about 440 kDa, and also has
been definitively shown to have approximately 5% of HA with
M < 100 kDa (37). The low M HA is proposed to participate in
stimulating the expression of human β-defensin 2 in the infant
intestinal epithelium (24). Human amniotic fluid contains HA
with an average M of about 330 kDa at 16weeks gestation, but
the M distribution changes to a mixture of high and very low M
HA by 40weeks gestation (92). HA in lymph fluid is variable in
size, and can occur as a mixture of high and lower M compo-
nents (36), or as a broad distribution of moderateM, ca. 800 kDa
average (93). HA in normal blood serum is mainly relatively low
M (ca. 100–300 kDa) (36, 56). It is also low in M in saliva and
urine (94, 95).
Tumors have been proposed to shed very lowMHA into associ-
ated body fluids. The quantity of such very low (but undetermined
size) M HA in patient serum, obtained by centrifugal filtration,
has been reported to be associated with metastatic breast cancer
(62). It has also been reported in saliva of patients with head and
neck tumors (95), and in the urine of patients with bladder cancers
(94). The precise size of all such HA has not yet been determined,
but should be accessible using recent improvements in methods.
Rarely, highM HA is found in serum, as, for example, associated
with Wilm’s tumor (96).
For solid tissues, the pattern is a bit simpler. Normal healthy
tissues are almost always associated with high M HA. HA with
average M > 2000 kDa is found in young human cartilage (53).
Larger HA averaging closer to 4000–6000 kDa is found in human
skin (54), in rabbit skin (34), and in rat skin (30, 97). HighMHA is
found in rooster combs (32). HighM HA is also found in skeletal
muscle, lung, heart, ileum, and colon of the rabbit (34). Little if
any lowM HA is found in these healthy tissues.
Remodeling tissues and tumors show evidence of some lower
M HA. Reduction in HA M occurs in older human cartilage
(53). Low M HA also occurs in healing rat skin wounds (30), in
human skin following irradiation with UVB (74), and in mouse
cervix undergoing postpartum remodeling (98). It is found in rat
kidney after ischemia–reperfusion injury (99). Human prostate
tumor HA has also been reported to contain some low M HA of
indeterminate size (67). Many of the above-described studies of
reduced M HA should be regarded as indicative but not conclu-
sive proof of the presence of specific low M HA species. Recent
improvements in techniques for analysis of very low quantities
of polydisperse HA will allow this uncertainty to be addressed.
Future studies should also include spiking samples with multi-
ple monodisperse HA species to show that the isolation meth-
ods cause no degradation, or preferential isolation of high or
lowM HA.
It is interesting to consider that all efforts to determine the
content and size of HA in biological tissues and fluids have made
the tacit assumption that the HA has a constant chemical struc-
ture, except for variation in size. Since degradation by ROS/RNS
can cause chemical changes including ring opening reactions, it
is possible that HA assays and size analyses may be influenced by
such changes, if present at significant levels. Further examination
of this possibility is warranted.
Conclusion
It is now well established that HA synthesis is significantly
increased in remodeling tissues and tumors. The concomitant
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presence of hyaluronidases andROS/RNSmakes it likely that frag-
ments of HA can be created by degradation of high M polymers.
The balance of synthetic and degradative activities, coupled with
turnover through outflow or internalization, will determine the
steady stateM distribution of the tissue HA. HA shed into lymph
or blood from a tumor may represent only the lowest M fraction
of that present. Whether HA fragments of particular sizes exist in
sufficient amountswithin a tissue or tumor environment to trigger
specific cellular responses is not yet clear. The fact that exogenous
HA fragments can elicit such effects is suggestive but not yet a
proof of their role in vivo. There is good reason to expect clarity
on these issues in the near future.
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